Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by PDT Partners LLC

Key Points

• PDT Partners LLC has reduced its stake in Supernus Pharmaceuticals by 32.0%, now owning approximately 0.07% of the company valued at $1.22 million.
• Analysts are optimistic, with Piper Sandler raising the target price from $36.00 to $40.00, and a consensus rating of "Moderate Buy" with an average price target of $43.00.
• Insider activity included significant sales, with SVP Frank Mottola selling 14,000 shares for approximately $623,140, and insiders selling a total of 179,606 shares worth $7.62 million last quarter.

PDT Partners LLC decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 32.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,381 shares of the specialty pharmaceutical company's stock after selling 17,627 shares during the period. PDT Partners LLC owned about 0.07% of Supernus Pharmaceuticals worth $1,224,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Supernus Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after acquiring an additional 1,083 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Supernus Pharmaceuticals by 14.7% during the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after acquiring an additional 1,000 shares during the last quarter. Principal Financial Group Inc. boosted its position in Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after buying an additional 9,590 shares during the last quarter. SG Americas Securities LLC boosted its position in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after buying an additional 6,867 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its position in Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after buying an additional 864 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 0.4%

NASDAQ:SUPN traded down $0.20 during trading hours on Tuesday, hitting $45.63. The company had a trading volume of 155,110 shares, compared to its average volume of 636,860. The company has a 50-day moving average of $38.29 and a 200 day moving average of $34.24. The company has a market cap of $2.56 billion, a P/E ratio of 39.67 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $46.78.

Insider Buying and Selling

In related news, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 14,000 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at $689,726.96. This represents a 47.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 235,184 shares of company stock worth $10,174,149 over the last quarter. Corporate insiders own 8.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Piper Sandler boosted their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Finally, Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.